Post by BeOne Medicines

Name: BCL-2 dependence is a key driver of tumour-cell survival across hematologic malignancies. But the
Uploaded: 2026-06-16T13:30:11.614Z
Channel: BeOne Medicines
Description: BCL-2 dependence is a key driver of tumour-cell survival across hematologic malignancies. But the full potential of BCL-2 inhibition has yet to be realised. Explore how BeOne is evaluating advance

253,627 followers

BCL-2 dependence is a key driver of tumour-cell survival across hematologic malignancies. But the full potential of BCL-2 inhibition has yet to be realised. Explore how BeOne is evaluating advancements in BCL-2 inhibition as a potential backbone of treatment across hematologic malignancies. Visit www.bcl2i.com. Intended for healthcare professionals only.

Video Content